Besides, due to the activation of RPS6KB1 in Xp11.2 tRCC, Trilaciclib, an FDA-approved CDK5 inhibitor, was expected to become a potential therapeutic drug (36). The gene discussed is CDK5; the disease is renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.